Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
RGNX logo RGNX
Upturn stock ratingUpturn stock rating
RGNX logo

Regenxbio Inc (RGNX)

Upturn stock ratingUpturn stock rating
$8.39
Last Close (24-hour delay)
Profit since last BUY-6.24%
upturn advisory
SELL
SELL since 4 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: RGNX (1-star) is a SELL. SELL since 4 days. Profits (-6.24%). Updated daily EoD!

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

12 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $32.5

Year Target Price $32.5

Analyst’s Price TargetsFor last 52 week
$32.5Target price
Low$5.04
Current$8.39
high$15.36

Analysis of Past Performance

Type Stock
Historic Profit -45.15%
Avg. Invested days 24
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 422.76M USD
Price to earnings Ratio -
1Y Target Price 31.75
Price to earnings Ratio -
1Y Target Price 31.75
Volume (30-day avg) -
Beta 1.09
52 Weeks Range 5.04 - 15.36
Updated Date 06/29/2025
52 Weeks Range 5.04 - 15.36
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.09

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -100.62%
Operating Margin (TTM) 13.62%

Management Effectiveness

Return on Assets (TTM) -17.56%
Return on Equity (TTM) -47.44%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 234740134
Price to Sales(TTM) 2.7
Enterprise Value 234740134
Price to Sales(TTM) 2.7
Enterprise Value to Revenue 1.5
Enterprise Value to EBITDA -3.37
Shares Outstanding 50388700
Shares Floating 41110421
Shares Outstanding 50388700
Shares Floating 41110421
Percent Insiders 7.7
Percent Institutions 87.66

Analyst Ratings

Rating 4.42
Target Price 32.5
Buy 5
Strong Buy 6
Buy 5
Strong Buy 6
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Regenxbio Inc

stock logo

Company Overview

overview logo History and Background

REGENXBIO Inc. was founded in 2009, focusing on developing gene therapies using its NAV Technology Platform. It has since grown through partnerships and clinical trials.

business area logo Core Business Areas

  • Gene Therapy: REGENXBIO focuses on developing gene therapies for a variety of diseases, leveraging its adeno-associated virus (AAV) based NAV Technology Platform.
  • Licensing NAV Technology: The company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies.

leadership logo Leadership and Structure

Kenneth T. Mills is the President and CEO. The company has a typical corporate structure with executive leadership and various operational departments.

Top Products and Market Share

overview logo Key Offerings

  • RGX-314: RGX-314 is being developed for the treatment of wet age-related macular degeneration (wet AMD). Competition includes Eylea and Lucentis. No market share data available directly. Revenue generated through clinical trials and potential future sales.
  • NAV Technology Platform: REGENXBIO's NAV Technology Platform is a key asset, licensed to various companies for developing gene therapies. Revenue is derived from licensing agreements, with no specific market share data available.

Market Dynamics

industry overview logo Industry Overview

The gene therapy market is rapidly growing, driven by advances in technology and increasing investment. It is characterized by intense research and development and high regulatory hurdles.

Positioning

REGENXBIO is a key player in the AAV gene therapy field with its NAV Technology Platform. It competes with other gene therapy companies and larger pharmaceutical companies.

Total Addressable Market (TAM)

The gene therapy market is projected to reach hundreds of billions USD. REGENXBIO is positioned to capture a portion of this through its pipeline and technology platform.

Upturn SWOT Analysis

Strengths

  • NAV Technology Platform
  • Strong intellectual property position
  • Experienced management team
  • Established partnerships

Weaknesses

  • Limited number of commercialized products
  • Dependence on partnerships for revenue
  • High R&D expenses
  • Clinical trial risks

Opportunities

  • Expanding gene therapy market
  • Potential for new licensing agreements
  • Positive clinical trial results
  • FDA approvals

Threats

  • Regulatory hurdles
  • Competition from other gene therapy companies
  • Patent challenges
  • Clinical trial failures

Competitors and Market Share

competitor logo Key Competitors

  • SPHR
  • VRTX
  • BLUE

Competitive Landscape

REGENXBIO's NAV Technology Platform is a key competitive advantage. Competition is intense, and success depends on clinical trial outcomes.

Growth Trajectory and Initiatives

Historical Growth: Growth has been driven by licensing agreements and clinical trial progress.

Future Projections: Analyst estimates vary and are subject to change. Consult financial analysts for projections.

Recent Initiatives: Recent initiatives include advancing clinical trials for RGX-314 and expanding the NAV Technology Platform applications.

Summary

Regenxbio is a gene therapy company leveraging its NAV Technology Platform. Its strengths lie in its technology and partnerships, but its weaknesses include reliance on clinical trial success and partnerships for revenue. Future growth depends on clinical trial outcomes and securing licensing agreements. Success hinges on managing regulatory and competitive pressures.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • REGENXBIO Investor Relations
  • Financial News Outlets
  • Analyst Reports

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate and may vary. Financial data should be verified with official sources.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Regenxbio Inc

Exchange NASDAQ
Headquaters Rockville, MD, United States
IPO Launch date 2015-09-17
President, CEO & Director Mr. Curran M. Simpson M.S.
Sector Healthcare
Industry Biotechnology
Full time employees 353
Full time employees 353

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.